<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19777206</article-id><article-id pub-id-type="pmc">2807589</article-id><article-id pub-id-type="publisher-id">1666</article-id><article-id pub-id-type="doi">10.1007/s00134-009-1666-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Glucontrol, no control, or out of control?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schultz</surname><given-names>Marcus J.</given-names></name><address><email>m.j.schultz@amc.uva.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Spronk</surname><given-names>Peter E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Braam Houckgeest</surname><given-names>Floris</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Intensive Care Medicine, Gelre Hospital, Location Lukas, Apeldoorn, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Intensive Care Medicine, Tergooi Hospitals, Hilversum, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>9</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>9</month><year>2009</year></pub-date><pub-date pub-type="ppub"><year>2010</year></pub-date><volume>36</volume><issue>1</issue><fpage>173</fpage><lpage>174</lpage><history><date date-type="accepted"><day>3</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Copyright jointly hold by Springer and ESICM 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Sir: Preiser et al. [<xref ref-type="bibr" rid="CR1">1</xref>] are to be congratulated on their randomized controlled multi-center trial on tight glycemic control (TGC) in critically ill patients. This trial adds to our knowledge of glucose control in intensive care units, but also poses a fascinating dilemma. While we need confirmation of the effects of TGC observed in Leuven, we notice at the same time that the Leuven trials have already changed the standard of care against which we compare TGC.</p><p>First, from this trial we learn that the intensive care community is increasingly practicing (some sort of) glycemic control. Undeniably, all randomized controlled trials focusing on TGC [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>], including this new trial [<xref ref-type="bibr" rid="CR1">1</xref>], show a change in standard care: &#x0201c;control&#x0201d; or &#x0201c;conventional therapy&#x0201d; patients are more and more treated with insulin and consequently have lower (mean or median) blood glucose levels (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This at least suggests that the intensive care community is realizing that glucose should not be seen as an innocent bystander during critical illness and that lowering blood glucose levels may have the potential to prevent injury to already threatened vital organs.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Blood glucose levels, percentage of patients treated with insulin and insulin dose (mean&#x000a0;&#x000b1;&#x000a0;standard deviation or median [interquartile range] in the control or conventional group (<italic>filled bars</italic>) and tight glycemic control group (<italic>open bars</italic>) of seven randomized controlled trials</p></caption><graphic xlink:href="134_2009_1666_Fig1_HTML" id="MO1"/></fig>
</p><p>This change in standard care, however, forced Preiser et al. and other investigators to face at least one significant problem. The observed diversity in composition of the &#x0201c;control&#x0201d; or &#x0201c;conventional&#x0201d; groups makes the successive randomized controlled trials fundamentally different from the very first trial of TGC [<xref ref-type="bibr" rid="CR2">2</xref>]. Indeed, these trials were all executed in the &#x0201c;flattened&#x0201d; part of the observational blood glucose level&#x02013;mortality risk curve [<xref ref-type="bibr" rid="CR8">8</xref>]. The hypothesized effect size in the trial by Preiser et al. (4%, absolute mortality reduction, similar to what was observed in the first randomized controlled trial [<xref ref-type="bibr" rid="CR2">2</xref>]) was therefore far too optimistic: according to the pooled analysis of the original two first randomized controlled trials [<xref ref-type="bibr" rid="CR9">9</xref>], the absolute reduction in mortality that could have been expected from further lowering blood glucose levels as compared with the &#x0201c;improved&#x0201d; standard care level was much lower. This would mean that tens of thousands of patients are needed to show this effect in a multi-center setting.</p><p>While the increased rate of hypoglycemia in the TGC control group was not considered as a safety concern (opposite to information given to the intensive care community on several conference occasions), the lack of difference regarding blood glucose control was a reason to stop the study prematurely. This definitely left us with an underpowered study. Indeed, this study does not help us in making an overall recommendation regarding the optimal target for blood glucose control.</p><p>Consequently, any advice regarding the blood glucose control target remains pragmatic: we all should assess whether hypothesized benefits were realistic, whether statistical power was sufficient, whether the targets were reached, and finally whether the levels of glycemic control diverged relevantly in the successive randomized controlled trials. If the above criteria are met, clinicians should determine how their own patients compare to the patients in these trials and decide which is the best target for blood glucose control in their setting.</p></body><back><fn-group><fn><p>An author&#x02019;s reply to this comment is available at: doi:10.1007/s00134-009-1669-z.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Preiser JC, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chiolero R (2009) A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 35:1738&#x02013;1748</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berghe</surname><given-names>G</given-names></name><name><surname>Wouters</surname><given-names>P</given-names></name><name><surname>Weekers</surname><given-names>F</given-names></name><name><surname>Verwaest</surname><given-names>C</given-names></name><name><surname>Bruyninckx</surname><given-names>F</given-names></name><name><surname>Schetz</surname><given-names>M</given-names></name><name><surname>Vlasselaers</surname><given-names>D</given-names></name><name><surname>Ferdinande</surname><given-names>P</given-names></name><name><surname>Lauwers</surname><given-names>P</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name></person-group><article-title>Intensive insulin therapy in the critically ill patients</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011300</pub-id><pub-id pub-id-type="pmid">11794168</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berghe</surname><given-names>G</given-names></name><name><surname>Wilmer</surname><given-names>A</given-names></name><name><surname>Hermans</surname><given-names>G</given-names></name><name><surname>Meersseman</surname><given-names>W</given-names></name><name><surname>Wouters</surname><given-names>PJ</given-names></name><name><surname>Milants</surname><given-names>I</given-names></name><name><surname>Van Wijngaerden</surname><given-names>E</given-names></name><name><surname>Bobbaers</surname><given-names>H</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name></person-group><article-title>Intensive insulin therapy in the medical ICU</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052521</pub-id><pub-id pub-id-type="pmid">16452557</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Dabbagh</surname><given-names>OC</given-names></name><name><surname>Tamim</surname><given-names>HM</given-names></name><name><surname>Al-Shimemeri</surname><given-names>AA</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Haddad</surname><given-names>SH</given-names></name><name><surname>Syed</surname><given-names>SJ</given-names></name><name><surname>Giridhar</surname><given-names>HR</given-names></name><name><surname>Rishu</surname><given-names>AH</given-names></name><name><surname>Al-Daker</surname><given-names>MO</given-names></name><name><surname>Kahoul</surname><given-names>SH</given-names></name><name><surname>Britts</surname><given-names>RJ</given-names></name><name><surname>Sakkijha</surname><given-names>MH</given-names></name></person-group><article-title>Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>3190</fpage><lpage>3197</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31818f21aa</pub-id><pub-id pub-id-type="pmid">18936702</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De La Rosa</surname><given-names>GDC</given-names></name><name><surname>Donado</surname><given-names>JH</given-names></name><name><surname>Restrepo</surname><given-names>AH</given-names></name><name><surname>Quintero</surname><given-names>AM</given-names></name><name><surname>Gonzalez</surname><given-names>LG</given-names></name><name><surname>Saldarriaga</surname><given-names>NE</given-names></name><name><surname>Bedoya</surname><given-names>M</given-names></name><name><surname>Toro</surname><given-names>JM</given-names></name><name><surname>Velasquez</surname><given-names>JB</given-names></name><name><surname>Valencia</surname><given-names>JC</given-names></name><name><surname>Arango</surname><given-names>CM</given-names></name><name><surname>Aleman</surname><given-names>PH</given-names></name><name><surname>Vasquez</surname><given-names>EM</given-names></name><name><surname>Chavarriaga</surname><given-names>JC</given-names></name><name><surname>Yepes</surname><given-names>A</given-names></name><name><surname>Pulido</surname><given-names>W</given-names></name><name><surname>Cadavid</surname><given-names>CA</given-names></name></person-group><article-title>Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial</article-title><source>Crit Care</source><year>2008</year><volume>12</volume><fpage>R120</fpage><pub-id pub-id-type="doi">10.1186/cc7017</pub-id><pub-id pub-id-type="pmid">18799004</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunkhorst</surname><given-names>FM</given-names></name><name><surname>Engel</surname><given-names>C</given-names></name><name><surname>Bloos</surname><given-names>F</given-names></name><name><surname>Meier-Hellmann</surname><given-names>A</given-names></name><name><surname>Ragaller</surname><given-names>M</given-names></name><name><surname>Weiler</surname><given-names>N</given-names></name><name><surname>Moerer</surname><given-names>O</given-names></name><name><surname>Gruendling</surname><given-names>M</given-names></name><name><surname>Oppert</surname><given-names>M</given-names></name><name><surname>Grond</surname><given-names>S</given-names></name><name><surname>Olthoff</surname><given-names>D</given-names></name><name><surname>Jaschinski</surname><given-names>U</given-names></name><name><surname>John</surname><given-names>S</given-names></name><name><surname>Rossaint</surname><given-names>R</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>P</given-names></name><name><surname>Kuhnt</surname><given-names>E</given-names></name><name><surname>Kiehntopf</surname><given-names>M</given-names></name><name><surname>Hartog</surname><given-names>C</given-names></name><name><surname>Natanson</surname><given-names>C</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name></person-group><article-title>Intensive insulin therapy and pentastarch resuscitation in severe sepsis</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>125</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa070716</pub-id><pub-id pub-id-type="pmid">18184958</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Chittock</surname><given-names>DR</given-names></name><name><surname>Su</surname><given-names>SY</given-names></name><name><surname>Blair</surname><given-names>D</given-names></name><name><surname>Foster</surname><given-names>D</given-names></name><name><surname>Dhingra</surname><given-names>V</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Dodek</surname><given-names>P</given-names></name><name><surname>Henderson</surname><given-names>WR</given-names></name><name><surname>Hebert</surname><given-names>PC</given-names></name><name><surname>Heritier</surname><given-names>S</given-names></name><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>McArthur</surname><given-names>C</given-names></name><name><surname>McDonald</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>I</given-names></name><name><surname>Myburgh</surname><given-names>JA</given-names></name><name><surname>Norton</surname><given-names>R</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>BG</given-names></name><name><surname>Ronco</surname><given-names>JJ</given-names></name></person-group><article-title>Intensive versus conventional glucose control in critically ill patients</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>1283</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810625</pub-id><pub-id pub-id-type="pmid">19318384</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Egi</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>C</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Early blood glucose control and mortality in critically ill patients in Australia</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318194b097</pub-id><pub-id pub-id-type="pmid">19114915</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berghe</surname><given-names>G</given-names></name><name><surname>Wilmer</surname><given-names>A</given-names></name><name><surname>Milants</surname><given-names>I</given-names></name><name><surname>Wouters</surname><given-names>PJ</given-names></name><name><surname>Bouckaert</surname><given-names>B</given-names></name><name><surname>Bruyninckx</surname><given-names>F</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name><name><surname>Schetz</surname><given-names>M</given-names></name></person-group><article-title>Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>3151</fpage><lpage>3159</lpage><pub-id pub-id-type="doi">10.2337/db06-0855</pub-id><pub-id pub-id-type="pmid">17065355</pub-id></element-citation></ref></ref-list></back></article>